Christopher Posner - Nov 28, 2022 Form 3 Insider Report for KEMPHARM, INC (ZVRA)

Role
Director
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Christopher A. Posner
Stock symbol
ZVRA
Transactions as of
Nov 28, 2022
Transactions value $
$0
Form type
3
Date filed
11/30/2022, 03:40 PM
Previous filing
Nov 18, 2022
Next filing
Feb 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZVRA Stock Option (right to buy) Nov 28, 2022 Common Stock 22.5K $4.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney.